Effect of interleukin-2 on diabetes in the BB/Wor rat.
Young diabetes prone BB/Wor rats were treated for 4-7 weeks with low dose (1,000 units/week) or high dose (75,000 units/week) recombinant human interleukin-2 (IL-2) and observed through 150 days of age for the development of spontaneous diabetes mellitus. Comparing treated rats with controls, it was found that IL-2 did not affect the cumulative incidence of diabetes, the age at onset of the disease, or peripheral lymphocyte subset numbers. High dose IL-2 administered to diabetes resistant BB/Wor rats also failed to induce the disease.
D000818:Animals; D004261:DNA Replication; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000503:physiopathology*; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation; D008297:Male; D051381:Rats; D011913:Rats, Inbred BB; D011994:Recombinant Proteins / Q000494:pharmacology*; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology
D007376:Interleukin-2; D011994:Recombinant Proteins